By
Dr Jordan Abdi2026-01-09T08:00:00
Procedural advances in IVF are reaching their biological limits. Reproductive biotech is now moving upstream, developing first in class therapeutics that target meiosis, gamete quality and implantation biology as druggable mechanisms in early discovery.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2023-05-31T15:16:10
Sponsored by Bio-Techne
2024-03-08T10:00:25
Sponsored by Molecular Devices
2023-12-11T10:49:07
Sponsored by Leica Microsystems
2025-05-08T10:38:52
Sponsored by Takara Bio USA
2023-11-24T12:06:45
Sponsored by Quantum-Si
Site powered by Webvision Cloud